AG
CCXI

Artal Group’s ChemoCentryx, Inc. CCXI Stock Holding History

Artal Group’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-400,000
Closed -$2.73M – 96
2014
Q4 		$2.73M Buy
400,000
+300,000
+300% +$1.59M 0.1% 79
2014
Q3 		$450K Buy
+100,000
New +$529K 0.02% 86

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Artal Group's CCXI Position: Q2 2021 in Review

Artal Group sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 750,000 shares — an estimated $38.4M sold.

Artal Group first reported a position in CCXI in Q2 2013 and held it in 21 quarters. The position peaked at $40.2M in Q4 2020. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

  • Artal Group reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
  • Artal Group sold 750,000 ChemoCentryx, Inc. shares in Q2 2021, an estimated $38.4M.
  • Artal Group first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 21 quarters.
  • Artal Group's ChemoCentryx, Inc. position peaked at $40.2M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.